India’s antivenom story is a paradox. The country is home to some of the world’s most advanced vaccine and biosimilar manufacturers – yet its snakebite treatment still hinges on a brittle, geographically blind model built around the so‑called “Big Four” snakes.
Commercial Indian antivenoms are produced by immunising horses with venoms from four species: the spectacled cobra (Naja naja), Russell’s viper (Daboia russelii), the common krait (Bungarus caeruleus) and the saw‑scaled viper (Echis carinatus). For decades, this cocktail has been treated as a national solution, supplied to district hospitals from Tamil Nadu to Uttar Pradesh. The catch is where that venom comes from.
Most manufacturers still source venoms from a narrow area in southern India – historically a few districts in Tamil Nadu – and use that as the immunogen for horses. Yet work from Kartik Sunagar’s group at IISc and collaborators has shown that venom composition is anything but uniform. Spectacled cobras collected across seven states, spanning India’s major biogeographical zones, displayed “astounding differences” in toxin profiles and potency. When researchers tested commercial antivenoms against these different populations, the results were sobering: some products showed poor binding and weak neutralisation, including near‑complete failure against certain desert cobras.
A parallel IISc‑led study on Russell’s viper told a similar story. Venom from different regions varied dramatically in composition and toxicity, and while antivenom performed reasonably well against most populations, it was markedly less effective against vipers from North India. In real‑world terms, two bites from the “same” species – one in Maharashtra, one in Rajasthan – may behave like different diseases, while the hospital administers an identical vial of serum.
This mismatch plays out against a brutal background. India is estimated to suffer around 58,000 snakebite deaths and 140,000 cases of serious morbidity every year, making it the epicentre of global snakebite burden. Delayed access to care, limited ICU capacity and lack of mechanical ventilation compound the problem. But even where vials are available, regional venom variation means patients are sometimes treated with an antivenom that was never designed for the toxins in their bloodstream.
Indian scientists are increasingly vocal about the need to rethink this “one‑size‑fits‑all” strategy. Proposals include region‑specific antivenoms, expanded venom banks that capture the true geographic diversity of key species, and investment in recombinant antibody platforms that could be rapidly re‑tuned as new data emerge. Policy‑oriented analyses have also called for stronger pharmacovigilance, better public procurement practices and WHO‑aligned quality standards.
For India, the stakes are uniquely high. Its snakes are both national hazards and global assets – the saw‑scaled viper alone inspired a blockbuster heart drug. Yet inside its rural clinics, clinicians are still forced to gamble on a vial designed for a different landscape. Closing that gap will require not just more antivenom, but smarter, geographically literate antivenom rooted in Indian science.Dr Durga Chandu
